section name header

Information

  1. Renan MJ. How many mutations are required for tumorigenesis? Implications from human cancer data. Mol Carcinogenesis. 1993;7:139-146.
  2. Sporn MB. The war on cancer. Lancet. 1996;347:1377-1381.
  3. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57-90.
  4. Mantovani A. Cancer-related inflammation: the seventh hallmark of cancer. In: American Society of Clinical Oncology Educational Book. ASCO; 2009:723-726.
  5. Goodlad RA, Plumb JA, Wright NA. Simultaneous measurement of intestinal crypt cell production rate and water absorption. Gut. 1987;28(suppl):189-192.
  6. Garrett MD. Cell cycle control and cancer. Curr Science. 2001;81(5):515-522.
  7. Lapenna S, Giordano A. Cell cycle kinases as therapeutic targets for cancer. Nat Rev Cancer. 2009;8:547-566.
  8. Weinberg RA. Mechanisms of malignant progression. Carcinogenesis. 2008;29(6):1092-1095.
  9. Wilkes GM, Barton Burke M. Oncology Nursing Drug Handbook 2009. Sudbury, MA: Jones and Bartlett; 2009:430.
  10. American Cancer Society. Oncogenes and tumor suppressor genes. http://www.cancer.org/docroot/ETO/content/ETO_1_4x_oncogenes_and_tumor_suppressor_genes.asp. Accessed September 9, 2009.
  11. Wood RD, Mitchell M, Lindahl T. Human DNA repair genes, 2005. Mutat Res. 2005;577:275-283.
  12. Bandipalliam P. Syndrome of early onset colon cancers, hematologic malignancies & features of neurofibromatosis in HNPCC families with homozygous mismatch repair gene mutations. Fam Cancer. 2005;4(4):323-333.
  13. Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol. 2005;23(3):609.
  14. Watanabe T, Kanazawa T, Tada T, Kazama Y, Hata K, Nagawa H. Chemotherapy and survival in colorectal cancer patients with and without microsatellite instability: can MSI be a good prognostic marker? Gastroenterology. 2004;127(2):688.
  15. Deng C-X, Wang R-H. Roles of BRCA1 in DNA damage repair: a link between development and cancer. Hum Mol Genet. 2003;12(1):113-123. doi:10.1093/hmg/ddg082.
  16. Zaniolo K, Desnoyers S, Leclerc S, Guerin SL. Regulation of poly (ADP-ribose) polymerase-1 (PARP-1) gene expression through the post-translational modification of Sp1: a nuclear target protein of PARP-1. BMC Mol Biol. 2007;8:96.
  17. Workman L. Cancer. In: Barton Burke M, Wilkes GM, eds. Cancer Therapies. Sudbury, MA: Jones and Bartlett; 2006.
  18. Trinchieri G. Biology of cancer: inflammation. In: DeVita VT Jr, Lawrence TS, Rosenberg SA, eds. Cancer: Principles and Practice. 8th ed. Philadelphia: Lippincott Willliams & Wilkins; 2008:193, 195.
  19. Galon J, Fridman WH, Pagès F. The adaptive immunological microenvironment in colorectal cancer: a novel perspective. Cancer Res. 2007;67:1883-1886.
  20. Colonna M, Trinchieri G, Liu YJ. Plasmacytoid dendritic cells in immunity. Nat Immunol. 2004; 5:1219.
  21. Manda G, Necchifor MT, Neagu TM. Reactive oxygen species, cancer and anti-cancer therapies. Curr Chem Biol. 2009;3:22-46.
  22. Psaila B, Lyden D. The metastatic niche: adapting the foreign soil. Nat Rev Cancer. 2009;9:285-293.
  23. Joyce JA, Pollard JW. Microenvironmental regulation of metastases. Nat Rev Cancer. 2009;9: 239-252.
  24. Newshad AS. Complexity in interpreting embryonic epithelial-mesenchymal transition in response to transforming growth factor- signaling. Cells Tissues Organs. 2007;185(1-3):131-145.
  25. Hay ED. The mesenchymal cell, its role in the embryo, and the remarkable signaling mechanisms that create it. Dev Dynamics. 2005;233:706-720.
  26. Mattila PK, Lappalainen P. Filopodia: molecular architechure and cellular functions. Nat Rev Mol Cell Biol. 2008;9(6):446-454.
  27. Ahmed S, Nawshad A. Complexity in interpretation of embryonic epithelial-mesenchymal transition in response to transforming growth factor- signaling. Cells Tissues Organs. 2007;185(1-3): 131-145.
  28. Fidler IJ. The pathogenesis of cancer metastasis: the “seed and the soil” hypothesis revisited. Nat Rev Cancer. 2003;3:453-458.
  29. Heimann R, Hellman S. Aging, progression and phenotype in breast cancer J Clin Oncol. 1998;16:2686-2692.
  30. Weinberg, RA. The Biology of Cancer. New York: Garland Science, Taylor & Francis Group, LLC; 2007.
  31. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumors. Nat Rev Cancer. 2008;8:755-768.
  32. Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer. 2009;9:265-273.
  33. Karnoub AE, Dsh AB, Vo AP, et al. Mesenchymal stem cells within tumor stroma promote breast cancer metastases. Nature. 2007;449:557-563.
  34. Shipitsin M, Campbell LL, Argani P, et al. Molecular definition of breast tumor heterogeneity. Cancer Cell. 2007;11:259-273.
  35. Nicoloso MS, Spizzo R, Shimizu M, Rossi S, Calin GA. MicroRNAs—the micro steering wheel of tumor metastases. Nat Rev Cancer. 2009;9:293-302.
  36. Gilmore TD. Introduction to NF-κB: players, pathways, perspectives. Oncogene. 2006;25(51): 6680-6684. doi:10.1038/sj.onc.1209954.
  37. Shih J-Y, Yuan A, Chen JJ-Y, Yang P-C.Tumor associated macrophage: its role in cancer invasion and metastasis. J Cancer Molecules. 2006;2(3):101-106.
  38. Wilkins-Port, Ye Q, Mazukiewicz JE, Higgins PJ. TGF-1+EGF-initiated invasive potential in transformed human keratinocytes is coupled to a plasmin/MMP-10/MMP-1-dependent collagen remodeling axis: Role for PAI-1. Cancer Res. 2009;69:4081.
  39. Wang X, Le P, Liang C, et al. Potent and selective inhibitors of the Met (hepatocyte growth factor/scatter factor, HGF/SF receptor) tyrosine kinase block HGF/SF-induced tumor cell growth and invasion. Mol Cancer Ther. 2003;2:1085.
  40. Mani SA, Guo W, Liao MJ, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008;16:133(4):704-715.
  41. Duffy MJ, Mcguire TM, Hill A, et al. Metalloproteinases: role in breast carcinogenesis, invasion, metastasis. Breast Cancer Res. 2000;2:252-257.
  42. Mansel RE, Fallowfield L, Kissin M, et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst. 2006;98:599-609.
  43. Ranieri JM, Wagner JD, Wenck S, et al. The prognostic importance of sentinel lymph node biopsy in thin melanoma. Ann Surg Oncol. 2006;13(7):927-932.
  44. Nguyen DX, Massague J. Genetic determinants of cancer metastases. Nat Rev Genet. 2007;8: 341-352.
  45. Chiang AC, Massague J. Molecular basis of metastasis. N Engl J Med. 2008;359(26):2814-2823.
  46. Ring BZ, Ross DT. Predicting the sites of metastases. Genome Biol. 2005;6:241-244.
  47. Andre F, Cabioglu N, Assi H, et al. Expression of chemokine receptors predicts the site of metastatic relapse in patients with axillary node positive primary breast cancer. Ann Oncol. 2006;17:945-951.
  48. O'Shaughnessy JA. Molecular signatures predict outcomes of breast cancer. N Engl J Med. 2006;355(6):615-617.
  49. Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumors. Nature. 2000;406:747-752.
  50. Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med. 2009; 360(8):790-800.
  51. Mook S, Van't Veer LJ, Rutgers EJ, et al. Individualization of therapy using Mammaprint: from development to the MINDACT trial. Cancer Genom Proteomics. 2007;4(3):147-155.
  52. Cardosa F, Van't Veer L, Rutgers E, Loi S, Mook S, Piccart-Gebhart MJ. Clinical application of the 70-gene profile: the MINDACT trial. J Clin Oncol. 2008;26:729-735.
  53. Liu R, Wang X, Chen GY, et al. The prognostic role of gene signature from tumorigenic breast cancer cells. N Engl J Med. 2007;356(3):217-229.
  54. Massague J. Sorting out breast-cancer gene signatures. N Engl J Med. 2007;356(3):294-297.
  55. Negrini M, Calin GA. Breast cancer metastases: a microRNA story. Breast Cancer Res. 2008;10:303-307.
  56. Vasudevan S, Tong Y, Steitz JA. Switching from repression to activation: microRNAs can upregulate translation. Science. 2007;318:1931-1934.
  57. Zaidi SK, Young DW, Javed A, et al. Nuclear microenvironments in biological control and cancer. Nat Rev Cancer. 2007;7:454-463.
  58. Yoo CB, Jones PA. Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov. 2006;5:37-50.
  59. Marks PA, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer. 2001;1:194-202.
  60. Richon VM, Sandhoff TW, Rifkind RA, Marks PA. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci USA. 2000;97:10014-10019.
  61. Ehrlich M. DNA methylation in cancer: too much, but also too little. Oncogene. 2002;21(35): 5400-5413.
  62. Esteller M. Cancer epigenomics: DNA methylation and histone modification maps. Nat Rev Genet. 2007;8:286-298.
  63. Lin JC, Jeong S, Liang G, et al. Role of nuceosomal occupancy in the epigenetic silencing of the MLH1 CpG island. Cancer Cell. 2007;12:432-444.
  64. Estécio MR, Gharibyan V, Shen L, et al. LINE-1 hypomethylation in cancer is highly variable and inversely correlated with microsatellite instability. PLoS ONE. 2007;2(5):e399. doi:10.1371/journal.pone.0000399.
  65. Larson PS, Schlechter BL, King C-L, et al. CDKN1C/p57kip2 is a candidate tumor suppressor gene in human breast cancer. BMC Cancer. 2008;8:68.
  66. Hedborg F, Igkssib R, Sandstedt B, Grimelius L, Hoehner JC, Pählman S. IGF2 expression is a marker for paraganglionic/SIF cell differentiation in neuroblastoma. Am J Pathol. 1995;146(4): 833-847.
  67. Shay JW, Wright WE. Telomerase therapeutics for cancer: challenges and new directions. Nat Rev Drug Discov. 2006;5:577-584.
  68. Blasco MA. The epigenetic regulation of mammalian telomeres. Nat Rev Genet. 2007;8:299-309.
  69. Vera E, Canela A, Fraga MF, Esteller M, Blasco MA. Epigenetic regulation of telomeres in human cancer. Oncogene. 2008;27:6817-6833.